• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.

作者信息

Kötter Ina, Zierhut Manfred, Eckstein Anja, Vonthein Reinhard, Ness Thomas, Günaydin Ilhan, Grimbacher Bodo, Blaschke Sabine, Peter Hans-Hartmut, Kanz Lothar, Stübiger Nicole

机构信息

University Hospital, Department of Internal Medicine II (Haematology, Oncology, Immunology, Rheumatology), Tübingen, Germany.

出版信息

Adv Exp Med Biol. 2003;528:521-3. doi: 10.1007/0-306-48382-3_104.

DOI:10.1007/0-306-48382-3_104
PMID:12918755
Abstract
摘要

相似文献

1
Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.用于治疗伴有威胁视力的视网膜血管炎的白塞病的人重组干扰素-α2a（rhIFN α2a）
Adv Exp Med Biol. 2003;528:521-3. doi: 10.1007/0-306-48382-3_104.
2
Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.人重组干扰素α-2a用于治疗伴有威胁视力的后部或全葡萄膜炎的白塞病。
Br J Ophthalmol. 2003 Apr;87(4):423-31. doi: 10.1136/bjo.87.4.423.
3
Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behçet's disease. A preliminary report.硫唑嘌呤和低剂量脉冲环磷酰胺治疗白塞病严重眼部病变：初步报告
Adv Exp Med Biol. 2003;528:571-3. doi: 10.1007/0-306-48382-3_116.
4
Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.脉冲环磷酰胺和硫唑嘌呤联合治疗 Behcet 病眼部表现：长达 10 年的纵向研究。
Int J Rheum Dis. 2014 May;17(4):444-52. doi: 10.1111/1756-185X.12248. Epub 2013 Dec 8.
5
Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.甲氨蝶呤治疗贝赫切特眼病：长达 15 年的纵向研究。
Int J Rheum Dis. 2013 Oct;16(5):568-77. doi: 10.1111/1756-185X.12139. Epub 2013 Jul 4.
6
High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results.高剂量甲氨蝶呤治疗白塞病眼部病变。初步短期结果。
Adv Exp Med Biol. 2003;528:579-84. doi: 10.1007/0-306-48382-3_118.
7
Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a.
Adv Exp Med Biol. 2003;528:529-32. doi: 10.1007/0-306-48382-3_106.
8
Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).利妥昔单抗治疗 Behcet 病难治性眼病变：随机单盲对照研究（初步研究）。
Int J Rheum Dis. 2010 Aug;13(3):246-52. doi: 10.1111/j.1756-185X.2010.01546.x.
9
Behçet's disease: visual acuity after 5 years in patients with alpha-interferon treatment.
Adv Exp Med Biol. 2003;528:525-8. doi: 10.1007/0-306-48382-3_105.
10
Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.干扰素α-2a治疗白塞病相关重度难治性葡萄膜炎的疗效
Ocul Immunol Inflamm. 2000 Dec;8(4):293-301. doi: 10.1076/ocii.8.4.293.6453.

引用本文的文献

1
[Rheumatological care in Germany : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024].[德国的风湿病护理：德国风湿病与临床免疫学协会2024年备忘录]
Z Rheumatol. 2024 Aug;83(Suppl 2):249-284. doi: 10.1007/s00393-024-01539-2. Epub 2024 Aug 13.
2
Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.贝赫切特病眼部受累的发病机制和治疗进展。
Front Immunol. 2023 Sep 29;14:1206959. doi: 10.3389/fimmu.2023.1206959. eCollection 2023.
3
Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.
穿越时光编织丝线：白塞病的过去、现在与未来
Int J Rheumatol. 2017;2017:2160610. doi: 10.1155/2017/2160610. Epub 2017 Sep 10.
4
High Levels of Serum Ubiquitin and Proteasome in a Case of HLA-B27 Uveitis.HLA-B27 葡萄膜炎一例中血清泛素和蛋白酶体水平升高
Int J Mol Sci. 2017 Feb 26;18(3):505. doi: 10.3390/ijms18030505.
5
Ophthalmic manifestations of rheumatologic disease: diagnosis and management.风湿性疾病的眼部表现：诊断与管理
Mo Med. 2012 Jan-Feb;109(1):53-8.
6
Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease.皮质类固醇节省型全身免疫抑制剂在炎症性眼病患者中的保留时间。
Br J Ophthalmol. 2006 Dec;90(12):1481-5. doi: 10.1136/bjo.2006.097998. Epub 2006 Aug 16.